Nature Communications (Apr 2021)

Lipocalin 2 mediates appetite suppression during pancreatic cancer cachexia

  • Brennan Olson,
  • Xinxia Zhu,
  • Mason A. Norgard,
  • Peter R. Levasseur,
  • John T. Butler,
  • Abigail Buenafe,
  • Kevin G. Burfeind,
  • Katherine A. Michaelis,
  • Katherine R. Pelz,
  • Heike Mendez,
  • Jared Edwards,
  • Stephanie M. Krasnow,
  • Aaron J. Grossberg,
  • Daniel L. Marks

DOI
https://doi.org/10.1038/s41467-021-22361-3
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 15

Abstract

Read online

Lipocalin 2 (LCN2) has been recently identified as an endogenous regulator of appetite. Here, using pancreatic cancer as a model of cachexia, the authors demonstrate that LCN2 is a critical mediator of cancer-associated anorexia and may be therapeutically targeted to improve patient outcomes.